Use of IgM enriched immunoglobulin in patients with severe bacterial infections in Intensive care

Registry on the use of IgM enriched immunoglobulin in patients with severe bacterial infections in Intensive care

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/015960

Enrollment

1200

Registered

2018-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A499- Bacterial infection, unspecified

Interventions

Intervention1: IgM enriched immuniglobulin: Inj IgM enriched immunoglobulin will be administered in a dose of 5 ml/kg body weight in each application. The medicinal product observed in the regis

Eligibility

Inclusion criteria

Inclusion criteria: Age >= 18 years Diagnosis of severe bacterial infection Ig M enriched immunoglobulin use signed informed consent for data collection

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
1.Documentation of Ig M enriched immunoglobulin use and definition of quality standards for Ig M enriched immunoglobulin use while addressing :1. Efficacy of Ig M enriched immunoglobulin use 2.Safety of Ig M enriched immunoglobulin use Timepoint: Upto 24 hours after last application	—

Secondary

Measure	Time frame
1. Comparison between APACHE II and SAPS II predicted mortality vs. observed hospital mortality 2.Difference in SOFA scores, baseline vs. posttreatment (24 h after last application) assessment. Timepoint: Upto 24hours after last application	—

Countries

India

Contacts

Public ContactRAJAT CHOUDHURI

IPGMER, Kolkata

rajat.choudhuri@gmail.com9874660960

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026